Abstract: An anti-CD33 antibody and a preparation method therefor and an application thereof. The anti-CD33 antibody has high affinity with CD33 protein, and therefore, can be used for preparation of a drug for treating tumor and the like.

Abstract: CD22 antibodies, a preparation method therefor, and an application thereof. The CD22 antibodies have a high affinity to CD22 protein Therefore, the CD22 antibodies can be used in the preparation of drugs for the treatment of diseases such as tumors and autoimmune diseases.

Abstract: The invention relates to an easy and mild method of encapsulating lipophilic compounds. To induce coacervation, no acid needs to be added. Therefore, the coacervate capsules of the invention may encapsulate lipophilic actives which are sensitive to acid degradation. In a preferred embodiment of the invention, a vegetarian rapeseed protein isolate is used to encapsulate vegetarian algae oil. The thus obtained product is a vegetarian or even vegan source of polyunsaturated fatty acids.

Abstract: The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Abstract: The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Abstract: A transdermal delivery device (10, 10?) includes at least one of a backing layer (14) and a removable release liner (16). An active layer (12, 12?) is supported by the backing layer and/or release liner. The active layer includes a polymer matrix, a therapeutically/cosmetically effective amount of an active agent dispersed in the polymer matrix, and a pressure sensitive adhesive, incorporated in the polymer matrix and/or adhered thereto. The polymer matrix includes a thermoplastic polyurethane polymer and optionally, a poly(meth)acrylate polymer. The thermoplastic polyurethane polymer includes the reaction product of: a first polyether polyol A having a molecular weight of at least 3000 daltons and/or a second polyether polyol B having a molecular weight of no more than 2500 daltons; a third polyol C having a molecular weight of up to 800 daltons and/or a chain extender; a polyisocyanate; and optionally a catalyst.

Abstract: The present invention relates to stable bioactive substances and preparation thereof. A preparation method includes dissolving a bioactive material in a solution substantially free of solutes to make a bioactive solution, adsorbing the bioactive solution onto dry polysaccharide particles to make bioactive loaded polysaccharide particles, and drying the bioactive loaded polysaccharide particles.

Abstract: The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: The present invention provides a method for coating seeds with biological materials such as bacteria, fungi (e.g., yeasts and molds), parasites, recombinant vectors, and viruses. The method comprises (a) applying a moistening liquid to seeds to moisten seeds, wherein the moistening liquid comprises a moistening polymer, and (b) coating the moistened seeds with an effective amount of a dry composition, wherein the dry composition comprises biological materials, one or more disaccharides, one or more oligosaccharides, one or more polysaccharides, one or more carboxylic acid salts, and one or more hydrolyzed proteins. The coated seeds may have an initial water activity (Aw) below 0.4, and the microorganisms on the coated seeds have initial viability of at least 5 logs of colony forming units per gram of seeds (CFU/g seed). Also provided are coated seeds.

Abstract: One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells. In some embodiments, the polysaccharide polymers of the present invention may also have one or more zwitterionic side chains and/or reactive side chains.

Abstract: A high drug loading system is described comprising of at least one anticancer drug; at least one peptide; and at least one nucleic acid.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: Dry stabilizing compositions for bioactive materials include sugars and hydrolyzed proteins, and may be formed into tablets or other forms providing enhanced stability for the bioactive material. Compositions containing the bioactive materials may be produced by a method that includes (a) combining the bioactive material with other ingredients in an aqueous solvent to form a viscous slurry; (b) snap-freezing the slurry in liquid nitrogen to form solid frozen particles, beads, droplets or strings; (c) primary drying by water removal under vacuum of the product of step (b) while maintaining it at a temperature above its freezing temperature; and (d) secondary drying of the product of step (c) at maximum vacuum and a temperature of 20° C. or higher for a time sufficient to reduce the water activity to below 0.3 Aw.

Abstract: The present invention includes compositions and drying methods for preserving sensitive bioactive materials, such as peptides, proteins, hormones, nucleic acids, antibodies, drugs vaccines, yeast, bacteria (probiotic or otherwise), viruses and/or cell suspensions, in storage. The compositions include a carbohydrates component and a glass enhancer component, wherein the carbohydrate component includes a mixture of di-, oligo- and polysaccharides and the glass enhancer includes ions of organic acid and protein hydrolysates. The composition is prepared by dispersing all the solid components in a solution and then snap-frozen to form small beads, strings or droplets. The preferred drying method of the frozen beads, strings or droplets is initiated by a short purging and structure stabilizing step of the frozen particles under a vacuum pressure of less than <2000 mTORR followed by a primary drying step under vacuum pressure of more than >2000 mTORR and at a desired temperature.